^
    2ms
    A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer (clinicaltrials.gov)
    P3, N=360, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Phase classification: P1b --> P3 | N=100 --> 360
    Phase classification • Enrollment change • Combination therapy • Mismatch repair
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
    4ms
    A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non-small-cell lung cancer who have progressed after anti-PD-1/L1 therapy. (PubMed, Cancer Med)
    IBI310 3 mg/kg Q3W plus sintilimab was effective in a small number of previously treated anti-PD-1/L1-resistant NSCLC patients.
    P1 data • Journal • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
    5ms
    A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy (clinicaltrials.gov)
    P2, N=205, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Feb 2024 --> Nov 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
    9ms
    A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer (clinicaltrials.gov)
    P1b, N=100, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Mismatch repair
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
    11ms
    A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer (clinicaltrials.gov)
    P1b, N=100, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P1 trial • Combination therapy • Mismatch repair
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
    1year
    PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment (clinicaltrials.gov)
    P2, N=40, Recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Recruiting | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    IBI-310 (ipilimumab biosimilar) • adebrelimab (SHR-1316)
    over1year
    IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Trial primary completion date: Oct 2021 --> Oct 2022
    Trial primary completion date • Combination therapy • Mismatch repair
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
    over2years
    Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (clinicaltrials.gov)
    P2, N=40, Recruiting, Peking University
    Clinical • New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • Sulanda (surufatinib) • IBI-310 (ipilimumab biosimilar)
    over3years
    IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient(dMMR)/Microsatellite Instability High (MSI-H)Locally-advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Active, not recruiting | N=68 --> 4
    Clinical • Enrollment closed • Enrollment change • Combination therapy • Mismatch repair
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
    over3years
    IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient(dMMR)/Microsatellite Instability High (MSI-H)Locally-advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=68, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting | Initiation date: Feb 2020 --> Aug 2020
    Clinical • Enrollment open • Trial initiation date • Combination therapy • Mismatch repair
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)
    4years
    [VIRTUAL] IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/1b study. (ASCO 2020)
    IBI310 monotherapy or in combination with sintilimab were well-tolerated without unanticipated AEs in pts with advanced melanoma. The data preliminarily demonstrate an antitumor activity of the combination therapy in previously treated advanced melanoma (acral and NCSD melanomas). Research Funding: Innovent Biologics, Inc.
    Clinical • Combination therapy
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Tyvyt (sintilimab) • IBI-310 (ipilimumab biosimilar)